Literature DB >> 16315601

Effects of epoxyeicosatrienoic acids on levels of eNOS phosphorylation and relevant signaling transduction pathways involved.

Ruijuan Chen1, Jiangang Jiang, Xiao Xiao, Daowen Wang.   

Abstract

Endothelial nitric oxide synthase (eNOS) is a key enzyme responsible for the regulation of vascular homeostasis. Many humor factors and mechanical forces can affect eNOS activity via phosphorylation modification but the mechanisms involved vary with stimuli applied. We have demonstrated that cytochrome P450 (CYP) epoxygenase-dependent metabolites of arachidonic acid, epoxyeicosatrienoic acids (EETs), can robustly up-regulate eNOS expression and its activity, however the relevant signaling pathways responsible for activity regulation are not well known. In this study, we explored the role of PI3 kinase (PI3K)/protein kinase B (Akt) signaling pathway in eNOS expression and its phosphorylation in response to EETs via direct addition of EETs into cultured bovine aorta endothelial cells (BAECs) and recombinant adeno-associated virus-mediated transfection of CYP epoxygenase genes CYPF87V and CYP2C11 to produce endogenous EETs followed by co-treatment with PI3K or Akt inhibitor. Results show that both exogenous and endogenous EETs could remarkably enhance eNOS expression and its phosphorylation at Ser1179 and Thr497 residues; PI3K inhibitor LY294002 could inhibit EETs-induced increase in eNOS-Ser(P)1179 but had no effect on the change of eNOS-Thr(P)497, while Akt inhibitor could attenuate the increase in phosphor-eNOS at both residues; both of the two inhibitors could block EETs-enhanced eNOS expression. These results lead to conclusions: (i) EETs-mediated regulation of eNOS activity may be related with the changes of phosphorylation level at eNOS-Ser1179 via P13K/Akt and eNOS-Thr497 via Akt; (ii) PI3K/Akt signaling pathway is involved in the up-regulation of eNOS expression by EETs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16315601     DOI: 10.1360/062004-36

Source DB:  PubMed          Journal:  Sci China C Life Sci        ISSN: 1006-9305


  5 in total

1.  Roles of endothelial nitric oxide synthase (eNOS) and mitochondrial permeability transition pore (MPTP) in epoxyeicosatrienoic acid (EET)-induced cardioprotection against infarction in intact rat hearts.

Authors:  Garrett J Gross; Anna Hsu; Adam W Pfeiffer; Kasem Nithipatikom
Journal:  J Mol Cell Cardiol       Date:  2013-02-16       Impact factor: 5.000

2.  1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia.

Authors:  Sampath-Kumar Anandan; Heather Kay Webb; Dawn Chen; Yi-Xin Jim Wang; Basker R Aavula; Sylvaine Cases; Ying Cheng; Zung N Do; Upasana Mehra; Vinh Tran; Jon Vincelette; Joanna Waszczuk; Kathy White; Kenneth R Wong; Le-Ning Zhang; Paul D Jones; Bruce D Hammock; Dinesh V Patel; Randall Whitcomb; D Euan MacIntyre; James Sabry; Richard Gless
Journal:  Bioorg Med Chem Lett       Date:  2010-12-13       Impact factor: 2.823

3.  ROS-responsive nanoparticle-mediated delivery of CYP2J2 gene for therapeutic angiogenesis in severe hindlimb ischemia.

Authors:  Liang Gui; Youlu Chen; Yongpeng Diao; Zuoguan Chen; Jianwei Duan; Xiaoyu Liang; Huiyang Li; Kaijing Liu; Yuqing Miao; Qing Gao; Zhichao Li; Jing Yang; Yongjun Li
Journal:  Mater Today Bio       Date:  2021-12-20

4.  Soluble Epoxide Hydrolase Inhibitor t-AUCB Ameliorates Vascular Endothelial Dysfunction by Influencing the NF-κB/miR-155-5p/eNOS/NO/IκB Cycle in Hypertensive Rats.

Authors:  Xiaorui Wang; Wenwen Han; Yi Zhang; Yi Zong; Na Tan; Yan Zhang; Li Li; Chang Liu; Limei Liu
Journal:  Antioxidants (Basel)       Date:  2022-07-15

5.  Implication of transient receptor potential vanilloid type 1 in 14,15-epoxyeicosatrienoic acid-induced angiogenesis.

Authors:  Kuo-Hui Su; Kuan-I Lee; Song-Kun Shyue; Hsiang-Ying Chen; Jeng Wei; Tzong-Shyuan Lee
Journal:  Int J Biol Sci       Date:  2014-09-06       Impact factor: 6.580

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.